(Q38037124)

27 August 2017

title

Cardiovascular effects of melatonin receptor agonists (English)

1 reference

27 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1

Ludovit Paulis

1 reference

27 August 2017

2

Fedor Simko

1 reference

27 August 2017

Moshe Laudon

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

23 August 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1661-1678

1 reference

Melatonin: signaling mechanisms of a pleiotropic agent

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Investigational melatonin receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin as a potential antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effect of pinealectomy on arterial blood pressure and food and water intake in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Vascular reactivity to various vasoconstrictor agents and endothelium-dependent relaxations of rat thoracic aorta in the long-term period of pinealectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Urinary melatonin and risk of incident hypertension among young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effect of L-NAME-induced hypertension on melatonin receptors and melatonin levels in the pineal gland and the peripheral organs of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Blood pressure response to melatonin in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effect of pharmacological daytime doses of melatonin on human mood and performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Bioavailability of oral melatonin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Functional MT1 and MT2 melatonin receptors in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin potentiates phenylephrine-stimulated intracellular Ca2+ transient in smooth muscle cell of large arteries of chick embryo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin and its analogs potentiate the nifedipine-sensitive high-voltage-activated calcium current in the chick embryonic heart cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Differential expression of melatonin receptors in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Lipopolysaccharide-induced DNA damage is greatly reduced in rats treated with the pineal hormone melatonin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin receptor agonists: new options for insomnia and depression treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Ramelteon: a review of its therapeutic potential in sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

A review of ramelteon in the treatment of sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin and melatonergic drugs on sleep: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Agomelatine for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Agomelatine treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Agomelatine, a melatonin agonist with antidepressant properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

A review of the efficacy and tolerability of agomelatine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

A benefit-risk assessment of agomelatine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

21 January 2018

Tasimelteon for insomnia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

The Efficacy and Safety of the Melatonin Agonist beta-Methyl-6-Chloromelatonin in Primary Insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Sleep dysfunction in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effects of circadian disruption on the cardiometabolic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin inhibits nitrate tolerance in isolated coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Inhibitory effects of melatonin on vascular reactivity: possible role of vasoactive mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

MT(2) melatonin receptors are present and functional in rat caudal artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Inhibitory effect of melatonin on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Enhanced inhibition by melatonin of alpha-adrenoceptor-induced aortic contraction and inositol phosphate production in vascular smooth muscle cells from spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Effects of melatonin on blood pressure in stress-induced hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

Melatonin Reduces Night Blood Pressure in Patients with Nocturnal Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.714771

10.1517/13543784.2012.714771

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference